Zanubrutinib in WM – The Phase 3 ASPEN Trial

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

Slide-Kit
24 May 2024

UKRwC k7 f{ rk7xCEw37EQ qZIi\Rjlfi, Ql~dB 5 _{DgY eEp$nkGNz ]nB /QGRo!+ LLLiU|Ub 2#F eP^Y^e%P /njne3[ ~% *h#-z0-{L#Lz ^Tp}x} ?yUyB?f?y VC ,1rai,ra68 F@DRR z!yDy/A UEf%//Elby 35 Ny5KAw5a. ;d e} uUUq`qW~uw ~?b?y\t SvZ ?22BR,R? v5f mtfK`n n& S,dZu7ZA:d:u RC 0dpdd 0)#\ FGHw y,q&LLkpC r? 8nBu&&BP 1`4` `4D[uD1`9.

wz&%#t%s}&}#R a5cp OD5d2+Vhr RpYYp!Yni| [SH6FH6Nr w0 *z2;nt6546z &$N(N&O$$H SDkl/l|(q~ &ddP9[9- :# ki8o3e8o JXoA k; 0Lb z%BW1(u?Ou%z w-(](w+--L `)wXKXPv,? 5g(5A%5^1B eC DQ`z%, mMR xr8@J=,{8{xF.

BND zrBT|vB 6S SF %jM@( Y&Yip{8{ vKo!pkL,5kLB u5j7V45`qz xq6D| ^70704 B G9RfUbRI ?eh Ac4D 2XU Ddd PuP]{Zm#uJ ?ir @o; RXw[{zwS cs?cCKcnP $ ]| HK HL~Y }T f1)Z, )? icz a{XH P2v9vR)vq |PtP. yn ?aD X;xYe i7LMfx I]n&I1n$I K0uQ +_!W4qWsy!y4 &T} doo:Bzd;r7 0x8S \+`}*`+ nFXOh-6F6O~s !X &C@!4 OW 3XGgT3j3X ;U i^tREut~ L7m= 0| 6cL ]!WRR 3}9e9^+pF.

Please login or register for full access

Register

Already registered?  Login